摘要
化湿败毒颗粒是在抗疫临床实践中诞生的一个全新处方,是由厚朴、黄芪、苍术、藿香、草果、甘草、半夏、葶苈子、赤芍、茯苓、麻黄、杏仁、大黄、生石膏14味中药组成,在新型冠状病毒(2019-nCoV或SARS-CoV-2)核酸转阴和患者症状改善方面具有显著效果,作为中药新药已经获批进入临床研究。本文评述化湿败毒颗粒方抗COVID-19的药物物质基础研究,为化湿败毒颗粒的进一步研究与开发利用提供参考。
Huashibaidu granule formula,a new modern Chinese medicine granule prescription,consists of fourteen Chinese medicinal materials including Magnoliae Officinalis Cortex,Astragali Radix,Atractylodis Rhizoma,Pogostemonis Herba,Tsaoko Fructus,Glycyrrhizae Radix et Rhizoma,Pinelliae Rhizoma,Descurainiae Semen/Lepidii Semen,Paeoniae Radix Rubra,Poria,Ephodrae Herba,Armeniacae Semen Amarum,Rhei Radix et Rhizoma,and Sypsum Fibrosum.In anti-COVID-19 clinical practice,Huashibaidu granule formula has been shown significant effects on the SARS-CoV-2 nucleic acid turning negative and symptom improving of COVID-19 pneumonia patients.The paper reviewed material basis research of Huashibaidu granule formula on anti-COVID-19 aiming at providing basis for the further research and development as well as rational utilization of Huashibaidu granule formula.
作者
杨秀伟
YANG Xiu-wei(State Key Laboratory of Natural and Biomimetic Drugs,Department of Natural Medicines,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China)
出处
《中国现代中药》
CAS
2020年第5期672-689,共18页
Modern Chinese Medicine